{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:30:37Z","timestamp":1767706237650,"version":"3.35.0"},"reference-count":7,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["acupunct electrother res"],"published-print":{"date-parts":[[2016,4,18]]},"abstract":"<jats:p>During the past 10 years, the author had found that the optimal dose of Vitamin D<jats:sub>3<\/jats:sub> 400 I.U. has safe &amp; effective anticancer effects, while commonly used 2000\u223c5000 I.U. of Vit. D<jats:sub>3<\/jats:sub> often creates a 2\u223c3 time increase in cancer markers. We examined the concentration\n of Taurine in normal internal organs and in cancer using Bi-Digital O\u2013Ring Test. We found that Taurine levels in normal tissue are 4\u223c6ng. But, the amount of Taurine of average normal value of 5.0\u223c5.25ng was strikingly reduced to 0.0025\u223c0.0028ng in this study of several examples\n in adenocarcinomas of the esophagus, stomach, pancreas, colon, prostate, and lung, as well as breast cancer. The lowest Taurine levels of 0.0002\u223c0.0005ng were found in so called Zika virus infected babies from Brazil with microcephaly. While Vitamin D<jats:sub>3<\/jats:sub> receptor stimulant 1\u03b1,\n 25 (OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> in normal tissues was 0.45\u223c0.53ng, they were reduced to 0.0025\u223c0.006ng in cancers (1\/100th\u223c1\/200th of normal value), particularly in various adenocarcinomas. All of these adenocarcinomas had about 1500ng HPV\u201316 viral infection. In 500 breast\n cancers, about 97% had HPV\u201316. The optimal dose of Taurine for average adult has been found to be about 175mg, rather than the widely used 500mg. In addition, since Taurine is markedly reduced to close to 1\/1000th \u223c 1\/2000th of its normal value in these cancer tissues, we examined\n the effect of the optimal dose of Taurine on cancer patients. Optimal dose of Taurine produced a very significant decrease in cancer\u2013associated parameters, such as Oncogene C\u2013fosAb2 &amp; Integrin \u03b1<jats:sub>5<\/jats:sub>\u03b2<jats:sub>1<\/jats:sub> being reduced to less than 1\/1,000th, and 8\u2013OH\u2013dG\n (which increases in the presence of DNA mutation) reduced to less than 1\/10th. The optimal dose of Taurine 175mg for average adult various cancer patient 3 times a day alone provide beneficial effects with very significant anti\u2013cancer effects with strikingly increased urinary excretion\n of bacteria, viruses, &amp; funguses, asbestos, toxic metals &amp; other toxic substances. However, optimal doses of Taurine combined with optimal individualized doses of \u03c93 fish oil [EPA 180mg &amp; DHA 120mg] &amp; special cilantro tablet 3 times\/day without creating harmful drug interactions\n among them including other essential drugs, is often extremely safe, more effective, economical &amp; non\u2013invasive new treatment for various cancer patients.<\/jats:p>","DOI":"10.3727\/036012916x14597946741564","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T01:44:04Z","timestamp":1460771044000},"page":"39-60","source":"Crossref","is-referenced-by-count":10,"title":["Optimal Dose of Vitamin D<sub>3<\/sub> 400 I.U. for Average Adults has A Significant Anti-Cancer Effect,While Widely Used 2000 I.U. or Higher Promotes Cancer: Marked Reduction of Taurine &amp; 1\u03b1, 25(OH)<sub>2<\/sub>D<sub>3<\/sub> Was Found In Various Cancer Tissues and Oral Intake\n of Optimal Dose of Taurine 175mg for Average Adults, Rather Than 500mg, Was Found to Be A New Potentially Safe and More Effective Method of Cancer Treatment"],"prefix":"10.1177","volume":"41","author":[{"given":"Yoshiaki","family":"Omura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Nihrane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha","family":"Duvvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Yapor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimotsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"4","key":"R56_303_437","first-page":"211","volume":"38","year":"2013","journal-title":"International Journal of Integrated Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1848-8846","issn-type":"print"},{"key":"R57_332_586","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/sj.ejcn.1601955","volume":"58","year":"2004","journal-title":"European Journal of Clinical Nutrition","ISSN":"https:\/\/id.crossref.org\/issn\/0954-3007","issn-type":"print"},{"issue":"2","key":"R57_133_398","first-page":"135","volume":"39","year":"2014","journal-title":"International Journal of Integrated Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1848-8846","issn-type":"print"},{"issue":"3","key":"R57_197_152","first-page":"157","volume":"40","year":"2015","journal-title":"International Journal of Integrated Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1848-8846","issn-type":"print"},{"key":"R58_329_199","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/B:CACO.0000019494.34403.09","volume":"15","year":"2004","journal-title":"Cancer Causes and Control","ISSN":"https:\/\/id.crossref.org\/issn\/0957-5243","issn-type":"print"},{"key":"R58_268_105","first-page":"3493","volume":"53","year":"1993","journal-title":"CANCER RESEARCH","ISSN":"https:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"key":"R58_287_70","first-page":"8","volume":"50","journal-title":"Proc. West. Pharmacol. Soc","ISSN":"https:\/\/id.crossref.org\/issn\/0083-8969","issn-type":"print"}],"container-title":["Acupuncture &amp; Electro-Therapeutics Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/cog\/aetr\/2016\/00000041\/00000001\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:51:18Z","timestamp":1738363878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.3727\/036012916X14597946741564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,18]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,4,18]]}},"alternative-id":["0360-1293(20160418)41:1L.39;1-"],"URL":"https:\/\/doi.org\/10.3727\/036012916x14597946741564","relation":{},"ISSN":["0360-1293"],"issn-type":[{"type":"print","value":"0360-1293"}],"subject":[],"published":{"date-parts":[[2016,4,18]]}}}